Amicus Therapeutics

Amicus Therapeutics, a public biopharmaceutical company headquartered in Philadelphia, PA, was founded with the mission to develop advanced therapies for rare and orphan diseases. The company went public in 2007 under the NASDAQ symbol FOLD. Amicus focuses on innovative treatments for conditions such as Pompe disease and Fabry disease, aiming to improve patient outcomes through cutting-edge science and compassionate care. Their market focus is primarily on rare and genetic disorders, providing hope and solutions for patients with limited treatment options.

Notable investors in Amicus Therapeutics include Radius Ventures, Canaan Partners, and New Enterprise Associates. The company has achieved significant milestones, including the development of leading therapies for rare diseases and the establishment of an expanded access program to ensure patient access to medicines. Amicus's impact is evident in their commitment to transforming the lives of patients with rare diseases, positioning them as a key player in the biopharmaceutical industry.